The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. While the integration of landmark trial data and new strategies is occurring on an ongoing basis, preclinical and clinical data continue to rapidly accumulate on immunotherapy basic science.
The rapid pace with which new and practice-changing information is emerging creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence of immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.
The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on scientific advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.
This educational activity is intended for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.
At the conclusion of this activity, you should be better prepared to:
Physicians' Education Resource - ECIC 19
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
|Physicians||EUR €199||EUR €249|
|Fellows*||Complimentary Registration*||Complimentary Registration*|
|Nurses, PAs, Other Health Care Professionals||EUR €199||EUR €249|
|Industry**||EUR €499||EUR €599|
*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.
**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.
For registration assistance, please e-mail email@example.com or call +1 (609) 378-3701 between 9:00 and 17:00 US EDT.
A cancellation fee of 25% will be assessed on refunds requested prior to 4 October 2019 and a 50% fee on refunds requested 5 October 2019 through 1 November 2019. No refunds will be made after 1 November 2019. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.
In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.
Physicians' Education Resource®, LLC, reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting continuing education materials.
By attending a PER® conference, meeting, or related activity (“events”), all participants, attendees, exhibitors, sponsors, and guests (“you”) create an agreement between you and PER® regarding the use and distribution of your image, including, but not limited to, your name, voice, and likeness (“image”). By attending the events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you, and you grant permission to PER® (and its agents) to utilize, in perpetuity, your image in any electronic or print distribution or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with all applicable laws, rules, and regulations, and as such, we may be required to collect information on transfer of value provided to healthcare professionals or healthcare organizations.
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular and Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA
Caroline Robert, MD PhD
Head of the Dermatology Unit
Department of Medicine
Gustave Roussy and Paris-Sud University
Villejuif Grand - Paris, France
May 30, 2019
May 31, 2019
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing Strategies
May 31, 2019
May 31, 2019